Journal of Clinical Ophthalmology - Dove Medical Press:
"Currently available uveitis therapies are burdened with toxicities and/or lack definitive evidence of efficacy. Voclosporin, a rationally designed novel calcineurin inhibitor, exhibits a favorable safety profile and a wide therapeutic window. If LUMINATE is successful, voclosporin will become the first Food and Drug Administration-approved corticosteroid-sparing agent for this condition."
No comments:
Post a Comment
Leave a Comment or Question: